From: <Salvato da Windows Internet Explorer 7>
Subject: Medical News Today News Article
Date: Tue, 13 May 2008 17:03:51 +0200
MIME-Version: 1.0
Content-Type: multipart/related;
	type="text/html";
	boundary="----=_NextPart_000_0000_01C8B51B.516272D0"
X-MimeOLE: Produced By Microsoft MimeOLE V6.00.2900.5512

This is a multi-part message in MIME format.

------=_NextPart_000_0000_01C8B51B.516272D0
Content-Type: text/html;
	charset="utf-8"
Content-Transfer-Encoding: quoted-printable
Content-Location: http://www.medicalnewstoday.com/printerfriendlynews.php?newsid=105601

=EF=BB=BF<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML lang=3Den><HEAD><TITLE>Medical News Today News Article</TITLE>
<META http-equiv=3DContent-Type content=3D"text/html; =
charset=3Dutf-8"><LINK=20
href=3D"http://www.medicalnewstoday.com/css/pagelayout.css" =
type=3Dtext/css=20
rel=3Dstylesheet><LINK =
href=3D"http://www.medicalnewstoday.com/css/default.css"=20
type=3Dtext/css rel=3Dstylesheet>
<SCRIPT language=3DJavaScript=20
src=3D"http://www.medicalnewstoday.com/scripts/AntiSpambotMailto.js"=20
type=3Dtext/javascript></SCRIPT>

<SCRIPT language=3DJavaScript>=0A=
// Script for printing=0A=
=0A=
<!--=0A=
=0A=
var da =3D (document.all) ? 1 : 0;=0A=
var pr =3D (window.print) ? 1 : 0;=0A=
var mac =3D (navigator.userAgent.indexOf("Mac") !=3D -1); =0A=
=0A=
function printPage() {=0A=
  if (pr) // NS4, IE5=0A=
    window.print()=0A=
  else if (da && !mac) // IE4 (Windows)=0A=
    vbPrintPage()=0A=
  else // other browsers=0A=
    alert("Sorry, your browser doesn't support this feature.");=0A=
  return false;=0A=
}=0A=
=0A=
if (da && !pr && !mac) with (document) {=0A=
  writeln('<OBJECT ID=3D"WB" WIDTH=3D"0" HEIGHT=3D"0" =
CLASSID=3D"clsid:8856F961-340A-11D0-A96B-00C04FD705A2"></OBJECT>');=0A=
  writeln('<' + 'SCRIPT LANGUAGE=3D"VBScript">');=0A=
  writeln('Sub window_onunload');=0A=
  writeln('  On Error Resume Next');=0A=
  writeln('  Set WB =3D nothing');=0A=
  writeln('End Sub');=0A=
  writeln('Sub vbPrintPage');=0A=
  writeln('  OLECMDID_PRINT =3D 6');=0A=
  writeln('  OLECMDEXECOPT_DONTPROMPTUSER =3D 2');=0A=
  writeln('  OLECMDEXECOPT_PROMPTUSER =3D 1');=0A=
  writeln('  On Error Resume Next');=0A=
  writeln('  WB.ExecWB OLECMDID_PRINT, OLECMDEXECOPT_DONTPROMPTUSER');=0A=
  writeln('End Sub');=0A=
  writeln('<' + '/SCRIPT>');=0A=
}=0A=
=0A=
// -->=0A=
</SCRIPT>

<META content=3D"MSHTML 6.00.6000.16640" name=3DGENERATOR></HEAD>
<BODY onload=3Dfocus() ;>
<DIV style=3D"BACKGROUND-COLOR: #ffffff" align=3Dcenter>
<TABLE=20
style=3D"BORDER-RIGHT: #000000 1px solid; BORDER-TOP: #000000 1px solid; =
BORDER-LEFT: #000000 1px solid; BORDER-BOTTOM: #000000 1px solid"=20
cellSpacing=3D0 cellPadding=3D3 width=3D600 border=3D0>
  <TBODY>
  <TR>
    <TD><IMG height=3D50 alt=3D"Medical News Today"=20
      =
src=3D"http://www.medicalnewstoday.com/images/title_printerfriendly3.jpg"=
=20
      width=3D332></TD></TR>
  <TR>
    <TD><IMG height=3D10 alt=3D""=20
      src=3D"http://www.medicalnewstoday.com/images/blanktab.gif" =
width=3D1></TD></TR>
  <TR>
    <TD>
      <TABLE cellSpacing=3D0 cellPadding=3D5 width=3D"100%" border=3D0>
        <TBODY>
        <TR>
          <TD vAlign=3Dtop>
            <H3>Brain Tumor Surgery: Study Investigates Connection =
Between=20
            Depression And Survival</H3>29 Apr =
2008&nbsp;&nbsp;&nbsp;<INPUT onclick=3D"return printPage()" =
type=3Dbutton value=3D"Click to Print"><BR><BR>Depression=20
            is one of the most common psychiatric disorders in the world =
today.=20
            It is estimated that in any given year, 5 to 9 percent of =
the US=20
            population is clinically depressed. Studies have shown that=20
            depression negatively affects the immunological system, =
alters the=20
            body's response to malignancy, and may influence behavioral =
factors=20
            that impact recovery from disease.<BR><BR>Psychiatric =
symptoms,=20
            including depression, often occur in patients with malignant =
brain=20
            tumors. Research has linked these psychiatric symptoms to =
tumor=20
            location and extent of the disease. In the past decade, =
studies have=20
            suggested that there is a relationship between depression =
and poor=20
            outcome in patients undergoing craniotomy for brain lesions =
as a=20
            whole. This association has also been reported after =
surgical=20
            therapy of non-neurological disease.<BR><BR>Malignant brain=20
            astrocytoma, also known as glioma or glioblastoma multiforme =
(GBM),=20
            is the most commonly diagnosed primary brain tumor. Glioma =
is a=20
            devastating brain cancer that typically results in death in =
about=20
            one year. The most effective therapies introduced over the =
past=20
            three decades have improved median survival by an average of =
only=20
            three months. Thus, identification of any reversible =
morbidity=20
            factors, which could potentially improve survival rates, =
such as=20
            depression, is of paramount importance.<BR><BR>Researchers =
at Johns=20
            Hopkins School of Medical in Baltimore analyzed the outcome =
of 1,052=20
            patients who underwent surgical resection and radiotherapy =
for=20
            glioma over a 10-year period. The results of this study, =
Association=20
            of Preoperative Depression and Survival after Resection of =
Malignant=20
            Brain Astrocytoma, will be presented by Matthew J. McGirt, =
MD, 4:01=20
            to 4:15 p.m. on Monday, April 28, 2008, during the 76th =
Annual=20
            Meeting of the American Association of Neurological Surgeons =
in=20
            Chicago. Co-authors are Frank J. Attenello, MS, Henry Brem, =
MD,=20
            Kaisorn L. Chaichana, BS, Muraya Gathinji, MS, Alessando =
Olivi, MD,=20
            Alfredo Quinones-Hinojosa, MD, Khoi Than, MD, and Jon D. =
Weingart,=20
            MD.<BR><BR>Currently, patient age, tumor grade, and =
functional=20
            status remain the known preoperative prognostic indicators =
of=20
            survival. "The goal of this research was to determine =
whether=20
            malignant glioma patients with a preoperative diagnosis of=20
            depression have a lower survival rate irrespective of =
treatment=20
            modality or degree of disability," stated Dr. McGirt. The =
research=20
            encompassed the following methodology:<BR><BR>-- The =
surgical=20
            management of 1,052 consecutive patients with malignant =
astrocytomas=20
            (WHO grade 3 or 4) performed at a single institution from =
1995 to=20
            2006 were reviewed.<BR><BR>-- Of these 1,052 surgical =
procedures,=20
            605 (58 percent) were for primary resection, 410 (39 =
percent) were=20
            for secondary resection, and 37 (3.5 percent) were for=20
            biopsy.<BR><BR>-- For the purpose of this study, only =
patients=20
            taking anti-depressant medication for clinical depression at =
the=20
            time of surgery were classified as having "depression." This =
equated=20
            to 49 patients (5 percent) of the total=20
            cases.<BR><BR>"Interestingly, all demographic and clinical=20
            characteristics did not differ between depressed and =
non-depressed=20
            patients. However, patients already depressed at diagnosis =
had a=20
            significantly reduced survival compared to non-depressed =
patients,"=20
            stated Dr. McGirt. This was most notable in survival rates =
beyond 12=20
            months, suggesting that depression may be most detrimental =
for=20
            long-term survival." Detailed findings included the=20
            following:<BR><BR>-- Regardless of patient functional status =
prior=20
            to surgery (KPS score), WHO Grade III vs. Grade IV tumor, =
patient=20
            age, or clinical presentation, those with depression had =
more than a=20
            40 percent increase in the relative risk of mortality versus =

            non-depressed patients. This association was independent of =
degree=20
            of resection or postoperative treatment modality.<BR><BR>-- =
At 12=20
            months post surgery, 41 percent of non-depressed patients =
were=20
            alive, while only 15 percent of depressed patients were=20
            alive.<BR><BR>-- At 20 months post surgery, there were no =
depressed=20
            patients still alive, while 21 percent of non-depressed =
patients=20
            were still alive.<BR><BR>Although patients classified as =
depressed=20
            were diagnosed prior to neurosurgical evaluation in most =
cases, it=20
            is uncertain that their depression was not a response to the =
recent=20
            diagnosis of a terminal disease. Many patients with clinical =

            depression may have been undiagnosed and off medication, =
lowering=20
            the sensitivity of the classification scheme and resulting =
in=20
            inclusion of clinically depressed patients in the =
non-depressed=20
            cohort. Further research investigating the survival of =
patients with=20
            non-medicated versus medicated depression is warranted to =
address=20
            these variables.<BR><BR>"In conclusion, this study does =
indicate=20
            strong evidence that there is a connection between the =
existence of=20
            depression and survival rates in patients with malignant =
brain=20
            glioma. Recognizing and treating depression preoperatively =
should be=20
            looked at more closely as a means to maximize survival in =
the=20
            treatment of malignant brain tumors," remarked Dr.=20
            McGirt.<BR><BR>Founded in 1931 as the Harvey Cushing =
Society, the=20
            American Association of Neurological Surgeons (AANS) is a =
scientific=20
            and educational association with more than 7,200 members =
worldwide.=20
            The AANS is dedicated to advancing the specialty of =
neurological=20
            surgery in order to provide the highest quality of =
neurosurgical=20
            care to the public. All active members of the AANS are =
certified by=20
            the American Board of Neurological Surgery, the Royal =
College of=20
            Physicians and Surgeons (Neurosurgery) of Canada or the =
Mexican=20
            Council of Neurological Surgery, AC. Neurological surgery is =
the=20
            medical specialty concerned with the prevention, diagnosis,=20
            treatment and rehabilitation of disorders that affect the =
entire=20
            nervous system, including the spinal column, spinal cord, =
brain and=20
            peripheral nerves.<BR><BR>American Association of =
Neurological=20
            Surgeons (AANS)<BR>5550 Meadowbrook Dr.<BR>Rolling Meadows, =
IL=20
            60008<BR>United States<BR><A=20
            href=3D"http://www.neurosurgerytoday.org/" target=3D_blank=20
            rel=3Dnofollow>http://www.neurosurgerytoday.org/</A>=20
            <HR SIZE=3D1>

            <P>Article URL:=20
            http://www.medicalnewstoday.com/articles/105601.php</P>
            <P><B>Main News Category</B>: Neurology / Neuroscience</P>
            <P><B>Also Appears In</B>:&nbsp;&nbsp;Cancer / Oncology,=20
            &nbsp;Depression, &nbsp;Clinical Trials / Drug Trials,=20
        &nbsp;</P></TD></TR></TBODY></TABLE><IMG height=3D10 alt=3D""=20
      src=3D"http://www.medicalnewstoday.com/images/blanktab.gif" =
width=3D1>=20
      <HR SIZE=3D1>
      <IMG height=3D10 alt=3D""=20
      src=3D"http://www.medicalnewstoday.com/images/blanktab.gif" =
width=3D1>=20
      <DIV align=3Dcenter>
      <TABLE cellSpacing=3D0 cellPadding=3D5 width=3D"100%" border=3D0>
        <TBODY>
        <TR>
          <TD bgColor=3D#ffffff>Save time! Get the latest medical news =
headlines=20
            for your specialist area, in a weekly newsletter e-mail. See =
<A=20
            =
href=3D"http://www.medicalnewstoday.com/newsletters.php">http://www.medic=
alnewstoday.com/newsletters.php</A>=20
            for details.</TD></TR></TBODY></TABLE></DIV></TD></TR>
  <TR>
    <TD align=3Dmiddle>
      <TABLE cellSpacing=3D0 cellPadding=3D5 width=3D"100%" border=3D0>
        <TBODY>
        <TR>
          <TD bgColor=3D#ffffff>Send your press releases to
            <SCRIPT =
type=3Dtext/javascript>AntiSpambotMailto('145|147|134|148|148|147|134|141=
|134|130|148|134|97|142|134|133|138|132|130|141|143|134|152|148|149|144|1=
33|130|154|79|132|144|142')</SCRIPT>
             =
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></DIV></BODY></HTML>

------=_NextPart_000_0000_01C8B51B.516272D0
Content-Type: image/jpeg; image/spj
Content-Transfer-Encoding: base64
Content-Location: http://www.medicalnewstoday.com/images/title_printerfriendly3.jpg

/9j/4AAQSkZJRgABAgAAZABkAAD/7AARRHVja3kAAQAEAAAAPAAA/+4ADkFkb2JlAGTAAAAAAf/b
AIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoKDBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxsc
Hx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8f
Hx8fHx8fHx8fHx8fHx8fHx8f/8AAEQgAMgFMAwERAAIRAQMRAf/EAKcAAQABBQEBAAAAAAAAAAAA
AAAFAQIDBAYHCAEBAAMBAQEBAAAAAAAAAAAAAAECAwQFBgcQAAEDBAEDAgQEAwUIAwAAAAIBAwQA
EQUGEiETBzEUQVEiMmEjFQhxQlKBkdFiM7GCklOUFlYXgyQ1EQACAQIEAwUGAwcFAQAAAAAAAQIR
AyExEgRBURNhcZEUBYGx0SIyBvBCUqHB4XKSogeCwiMzJBX/2gAMAwEAAhEDEQA/APn2v008cUAo
BQCgFAKAUAoBQCgFAKAUAoBQCgFAKAUAoBQCgFAKAUAoBQCgFAKAUAoBQCgFAKAUAoBQCgFAKA+n
PHuja/E8F5JjJRI72x5vEZPMxCeaFx1hgWkaYMDVOQJ1BwbeqktfJ77eT80nFvRCSXfz+B3Wra0Y
5spl9HwGu/tyycGRCju7RDgxpuRfJoSfYcmyBcFvuKPIVAE42Rfx+NZrfTnulKr0V9yJ6aUKcTz3
HeINUxuG16VvOwP4rJ7RxLGYyLG7xg0aigG+Sr9N+4PS3S/xstvTl6rNuStxTUc237jFWVhV5mzG
/b6MfZNoZz2cDG6tqpNJMzStKRO99oH2wBtFWxdt0eXVeqoiIt6mXrNYRcY1nPgPL4urwR0mf1TR
MJ4RYa1iSmec2/MMQ8VlpEXtSU5OILgMo6AuCN4pJe3838K4VvrktxWfy6I5J4fjE06aUMOJm3Hx
AxnNyexsvIY/D61puJYLMZeJC9sqk4hGgmHdd7jnaBCI1JLX+35tv6m7cKpOU5ywTdROzV9iPLs/
r3ihvM4SFrWzzMzFmPqGWfSC8Bx2UIEQm2zACcJUUugovpXqWd7ecZOcVFpYY5mMrcaqjOoz3hnS
2/HuZ27BZ6e6OHIBNrIQTio4ZkA8B5oBde4llRF61z2/VrnVUJxjjydSzsLTVMt82QMZrnj7x7r7
UNhrLPwlyGUkC0AvqRgHETcRORJyccTqv8qVTY7iU79yVXprRFrkKRSJT9qut4edlM/mc3Hjv46F
HYiikwGzZR2S7dFs4ipyTtWv/m/Gp9d3EoxjGLabxw7CNtFNts6GZ45i6ThPKs57GtSW5T7UHV23
GgcUSnJZv26EhLyApgD0/orh8/K7K0q0p9Xs5+Bp0lFM5aL4H02PsON0vNbS8zu2RY7yw40TuxmS
VsnEbN3l9S8QX5X/AA6V2v1i5pc4wWhduJn0FWjeJB5TwsTOk4fLY+U7KzuSzp6+5A4p2ReB2Qzz
FxPq4qscV6p0v+FdEPVk7ji1SCjqr4fEq7GHbU6DL/tzYheTMNqUfIvvwJsB3IZHJEAh7dtlSElT
7htyQE6/1fD1rGHrVbMptLUnRLmWe3+ZI1pXhrx7h9bj7LsWzzIuIyjziYc48In1KMJKjbrxByEV
dGxInT1T1W9n/wBa7KWiMVVZ48R0ElVs8kzYYVvLy2sJIdlYptxRiSXx7bjgJ/OQJ9t1+FexYuyl
FOWEjnkqPA0q3KigKXqKg6bx5p6bZsrWMek+xxzTTsvKZBUuMeKwCm44t7J8hS/xWuXebnow1JVe
SXNmluGp0NPdNYk6vs07CvmjyRjvHkj9rzDiIbLw2v0cbJCqdtuVdgpLj7yJw0uhCotdKZQrUgUA
oBQCgFAKAUAoBQCgFAKAUAoBQCgFAKAkdbxsXJ7BjsfMlNwYkqS01JmPmLbbLRGiG4RmqCnEbr1r
K/Nwg5JVaRaKq6H0hr3lDUx8/wCXR/Kw4uo47AJisY+UhpYhoybDtgPkokq3cRERVVbf3fHXdtPo
LB63Kr5nfGa1dhz2M8k4HYvHXlHJZjIRo+Szk7nExrshtuS5DZbaFltpszEjUWxUfp9VqHt5RnBJ
YIak0zs923BM3Oi5PTvLeH1zADFbBzGmsdXhISJSMWT/ADb8CFOFk9LVjat0wlbcmWk+TOMh53Wt
z8JZXEZHdYuNzsjKu5DJv5QxB6S20aK1ZpFEju023xRtFso8bV1StytXk1GqpwKJpxzJiZk9DY3H
xVrDGx4x7XtVjOzpuTSXG7JS2m07XMu4QAavN8uPL+b42rJRm4zlpeqXChaqqkY2dv1DetU8ha+/
tEHXcxms2483LmuADTsJhWAjoLqmIkJNRuP0l/ZZep2p25QlpbSQqmniaPiXFePNNmbTBjbxiF2Z
zHNNY3YHSaCKw893u4kdxw+DvGzKkqL+Fui333U5zjF6HpriueWf7SkEk3jiXbhsmKmeNNX1Cdus
TYJmZzrSZ7JnMBUahC8S8nBI+bTaCgKnO3otZQg+pKajposFQs3hSp55+4zaYOx+U5TuOlNTcZAj
R4kKTHcB5kgQO6XA21IbI46Setel6TZcYKqxMb8qsmYew4jX/wBtkyHAycb/ALj2DKAUiI0+37xl
ho04qTSF3BH/AOt62/n/ABqN7CU91inpjH2fjEm20oHou2+cNTy2J8ZyJc+Oqv5OLkNhYAxcOKUM
FRe80FyAfcOIY3RLoN0ryY7ScXNU4YG7mnQxeQdvzQS8vnsP5gxjeE4G/BwkNYr8zo3cGAFORciN
Lcl9L3WrWLSdIu268yJS41I/xx5P1bAeB1nZKfEkbPiJUyXjMc6+BynJj5GDTpMKvcJLySVVt6XK
r7rbT61EnpaREJrSZvJnl3Ah4ixJYrJxpm67HioeMyDjMkHnorJNI5LR7iSq0RGagvKy3X/LWdix
LqYr5U6kykqEl46nt6KIRcv5WwGY0uE06P6QLkd+QraiSALfEjd9VReCKSW6IlTuIu5irclPmIun
HA+Zc5Oi5TY8tPxsb28KZMkSIkUBREaZddI2wQR6IgiSJX02zlpgtTOO4qs1fbyf+Uf/AArXZ1o8
14melnqegQtX0zDQ9q3TGt5E8++kPFYmQiLwgoaJMnkCp8E+hr0ut19OteVu7s70nbtOmlVbXPhH
4m8IqKq+Jw2+6y5q235TBmvNuI8vtnei9yOaIbDnTp9bRCtd213PVtqXP38TOcKOh0sZf+1vD8iW
v0Zbd31ix1/mHFwSQniRUW6d6RYPxQa5Jy6u4S/Lax/1P4F0qQ7y+ehbr4vjZJtFd2LS0CDPFOpv
Yl0l9s7a919u4qtrZOgqirVIS6N5r8lzFdkuPiS1qj2o4KPiss+KkzCfdFFspA2ZJf5dEr0lfjzX
iY6WY3mH47pMyGyZdG3JtwVEkul0ui9fSuiMk1VFWiyrECgFAKAUAoBQCgFAKAUAoBQCgFAKAUAo
CipdKhqoLO0NY9BFtRTsjUeXROsp7cap5WJOsqrAqlWe3TI1lEjilQtqkNZXsDUvbRGsp7cbVHlU
NYSOKVC2qROs9G1bwZsGw4hvKQstiGQNr3DsZ+S4j7LfWxPADTiAionLqvpXxPqf3ztPT77szs7i
TUtKlGC0yfKLc1XllmddvZynGqcfEMeDtgl5ORFjZXFSIcJgZGQzDUklgsIakiAbqgP18QUlREsi
WuqXpuPvraRtRnO1fjcuScYWnD/klSmKjq+mronXF1onQR2cq0TjRceBHbt4lzGr4iJm1mwsthZh
9pnIY91XW+aoSoirZPXgXVLp0rq9D+6dt6jfnt9FyzfgquFyOl0w+KwdGVvbeVtKVU4vkTh/tz2R
vIMY53PYJnJyQRxjHOS3QkmK3soskyhr9q/D4V4kf8g7N23ejY3TtRdHNW4uCf8AMp04rxNvJTrT
VGvf/A4xjRc5I3IdQRoRzCylhkKqqtiQr9RqQoS8BFOSkifb1r6696xtY7DzzdbGjX2tcFjT5m8K
VzwOVW5a9HGpMZnw9n8Pu2N1CZLgjkco2DkZ8XHVjp3DNsBIlaQ0JSaVPs+VeTsfuvabnYXN9bhc
6VltSVI6sFFtpaqUpL9XM1nt5xmoNqrMeP8AEexTstn8eb0WGGtIZZSfJNwYwoBKicTBsyXmIqQ3
FLonz6Vpu/ujZ27O3upTm91Tpwio68eacksHRPHN8sSIbebclgtOZz+C2PPa5KObg57+OluNqyb8
Y1bNWyVCUFUfgpAi/wBlfT3tvBwpJVVTnjJ1wJ3/ANyeU/8AynJf9Q5/jXH5Kx+hF+pLmc9ndkz2
fmpOzU9/Iy0BGxfkuE4SAKqqCikq2S6r0re3bjBUiqIq23mekT8JM8h6npeSx4oeZYkN6plF6fBe
cF4kTrx7KkJEv9NcMLqsTmn9P1r96NXHUl4HOeXs9CyW3nAxRXwevst4fEp0VFZiJwJy6Wv3XOR3
+N632UHG3V/VL5n7Stx1fcc5gNkz+vTCm4PIP46WYK0b0Y1bJQJUVRVR+FxRa6LlmNxUkqoopNZH
Qf8AuLyn/wCU5L/qXP8AGs1sLH6ET1ZcyAyuYyuZnu5LKynZs9/j3pT5Kbh8BQB5EvVbCKJXpWLc
YQUYqiMpNt4mnWjKlakCgFAKAUAoBQCgFAKAUAoBQCgFAKAUAoBQCgFAKAUAoBQFFqGSew6Iia/4
L3DPl9MjMuDjIy/FQsjaqi//ADuf8NflX3E/O/cWz2y+mwndl3/V/sj4npWPksSlzwMmSbew/wC2
vFNQWyJzYsipT3GxVUVENziKqnxX27Y/31jtpx3P3XdlceG2tfIn3Rq/75PwJktO2VPzM6Adedh6
l410CaKjkcnkkymRir94R2lN9wCS30rwct/EV/GvDfqau731H1O3/wBdqz0oS4OT0xTXPGPg12G3
TpC3bebdS6BBn7L+5KbljacHEa+pIcgxUW09sz2UHmqcbq+Sl/C9V3G5t7H7WhYTXW3FMOPzy1ZZ
/RRd9CYxc9y3wiUxMOI01s2+yMrCwuV2t6VH1aTkXO0LcPnxKQKIilzILcbJ8l9Cqd3uJye29Nja
uX7O0jCV+NtVrOlVB8NKeftWcRGK+a5VJyrSvIg/Prk6Ht+mzIhi/MagRijPtL0ceaeUhUF6LZSV
FT+Net/j1W7mx3lua0wldnqT4RlGjr7MzLfVU4tZ0M/7jNoDHyi1XFgkb9SUMlnnG16vOqiA02S/
gjSEv+7+NYf419Kd6C3l56ulW3ZT/LHOTX9TS9vYW39yj0Ljizwhbr61+uurPLCDTSKleNToFTrd
D8m7HpDOWaxHaVMvH7DiuoSq0aISA+1xIbOtoZcVX5+lce62UbrWr8v4oaQuOJyNlVbr611KJSp6
Kx4viS4EiRDlOm68zjXcO0qCqurKFpZgn0T/AECf6cflXJ5tppNfqr7K08aF9BnDxlgZj0hzHznz
goxPCIZ8FJydGme3itXQUSzrbjTipa/r19Kh7ucUqpVrHwaq/DEaEY4/jnCG6LZTX09g5AXOW4fl
syMc5Pkk39Pqysdxvrf4XrTzk0ss9Wn2S0rxqmR00Qm66jH1v2rCvG5NeenIYlx4diNKOIyY2Trz
Nhzr6fKura7h3avhh4tVfvRScaHYS/G+hxpuRjlKyhfpGSx+NlKnt/zf1IHFEm+n0dpWVvfly+Q3
unJHeXmk6R+aMnx/LT3l3biY4HiLFrHkLkMgTSnOyMGJLV6Iwy1+nrwF19t8xccR1xbcWvtTrdb2
q0/UJVVFwi8m/q5U5doVpFsHV9cxet59s1ek50tXi5QydBso7aTZUN0Oz05g4206IqV/q5F6W6zK
/OU48IdRx7cFLMKKSfOhbtema1jsxm5menSkYPOTMREeissBwKMAOuPustgAKP57aI20IfG3ypY3
M5RioJfQpOtePCvseLqRKCTdeZot+PcS9pEvMgU1mdExzeT7khGW2H0OSEc22WFVJBAHdT89Lgqp
bpdK0e7krqjhRypxqsK4vL2ZkdNaanWZvx1qWT3ia1JOVDdy+1T8HBZhCyEdgWgYNtxRIb2QpFlA
bXT4pbrx2t5cjaVKPTbjJ1rV5/A0dtOXtoctD8a4wtMay8yYTE6XjZWVimT8UGBSM46ARyYM0kOG
97cuJAlkVRSy9bdct7Lq6UsFJRyfGmNcsKmatqlSQb8Q4uS8oRZzypIyEJuEpcP/AM2UMMjkOdE6
j+qMWXoPrWb9Qklisouv8y1Yf2st0l+Px2kY/pmmBrS5qPKnTmWwCS+7HVkgbQpnZ9m+Aibsd1Wf
rF5wUbIuiD1rVbm7r0tJcOPKtVzVeCxK6FSpO7bpOmubrsL7gycfi0zwYSJEhCyiNvv9wjdQeAij
LSAnFpEut/uS1c+33N3pRWDlo1Y1y+L5l5QWp95brGi4HC5JhnLG5LzMuDsDkdpAbOGgwGJkVOYm
nPn3I5uCSL9Nh6dbpN/dTnFuOEU4d+Li/wB9CIwSePaRi+O9cb1j9ZkO5CMEQcbIlm+jDffjzjEH
ijx1/PAW1P8ALdJCE7X+Na+cn1NK0uuqmeDWVXl3rgR01SpA7tprGsNsMOPG5kHZmQaIVt2/axH/
AGzLo2S69xxt3re1kS1b7bcu7V8KR8Wqv9xWcNJMO+PdbLaIeos5CS3nRlR4+QecbAo5A40rshxh
BsQ9hfpQTVefrcfSsVu59N3Gloo6c+yvf+wnQq04l8PQ9TmQ0zjcieGELGTZwxy7KykfgPtNE2p8
UbUHBeEkLj9N/jbrEt1cT0Ujq1JcaYp/AlQWfAt2TQtXh4XJTcZKmlIhwsVlGwko1w7GVBskZLh1
U2+6i8+iL6cUtdZs7q5KSUkqNyjhzjxIlBUw7DzyvRMhQCgFAKAUAoBQCgKLVWSS8jcdjf1ePqzk
u+Ciuq+xDRtobOKpkpK4go4XVwvuL/YleNH0Taw3kt4of+icdLlWWWC+mulfSsl72a9aTjor8pKa
p5a33VYC47D5LtwOSmMZ1tt4QIluSh3BJRuvWyLb415PrH2h6d6hd6t+3W5lqTcW++jx95ra3VyC
ongaY+Sd3HaE2lcoZ50QJsJjjbTnACRUUQbMCbEbEvQR+NbS+2dh5TyfSS29a6U5Kr5tp6m8Fmx5
ierVX5iRy3mvyhloD0CdnXCivioPA0zHYUhJLEKmy22VlT1S9cG0+yPSdvcVy3YWuOKrKcse6Umi
8t3dkqNkBsW37Fsaw/1iX7lMeykaGCNtNC20PoIi0ID/AG2vXsem+j7bZa+hHT1JapYyk3LnWTbM
rl2U6VeRs5Pfdsyk7FTp85HpWERtMY4rLA9pGiQgTiIIJ2UU+9FrLafb+z29u7btw0wv11rVL5tS
o85VWf5aEyvzk028sjS2LY81seVcyuZke6yDwiLj3Btu6AKCP0tiA9ET5V2+memWNlZVmxHRbVaK
reeLxk2yly5Kbq8yPRK9JIzKolXSIqVtVqEFFGquJNQg1CiKnWYnyVsuLTBJFVi+ujKHHkQKqr7z
71cVCTkoLZQ/pslc89jblqrX56V9hZXGqdhq4jeM3isTGxcTtJGiZNrMMkQXNJLQiiJyv9hdsFIf
iopWtzawnJyebjp9hCm0qFzW9Z1qZn5Q9rubI281PRQVUFHyUiVnr9CohECev0qqVD2kGor9GXsG
t49pZmtyyeaJw8gxGddKGxAbdVteTQRzE0NpVJeLhqK8y+PIvnVrW2jD6a5t+Ic2zYk+Qs9Ik5CQ
4LHcyc2HkZNgJE70BHEZ4/V0H84uSfGqx2kEksflTXjmOozOz5N2Jr3Jo3FKS7JlzI0o2uTsR6el
pBRiUvp5p/UhcfVLL1qHsoOmdKJd9Mqk9RmNfIuaXBPYgo8QkkQW8W9PVpfdFEZdB1ptXOVvoVsR
T6ft6LeyWeTjr1VeeqnCpHUdKGyPlfaEnz56hFKVNmuZRpwmlVYsx4eBvRrl9JcbJ9XJOiL6oi1X
yFuiWNEtPeuTJ6rMAeSMymHPGHEhOi7j/wBJdlmyvuCiCSG0CmJD/pEIqKonWycuVqt5OOrVV/Vq
7K/xHUdKGVzynszmYj5Yhje6jZh7PNojZcPdyBaE0VOX+naONhv8+tQtjb0uONHHT7FX4jqOte2p
pRt8zUfBJiWwjr24z0BieTV5TcOSZOPRwcvbgZOH6jdEIkRURavLaxc9WOdacKrJka3ShtR/J+zx
whg2rCeyxruJZXgt1Ydt9ZWLq4HAOJfDiPTpVXsbbrnjLV+OwnqM13d/zbmBLEE1GTnEbxzs9GrS
jhNOi83HI78eAm2PXjysiJe1WW0ip6sc604VyqRrdKG8flXYHMrMyTsSA69OkMz3mjYUmknMcuEs
AU+jv5hXT7F+I1n5CGlRrLBUz4Ph3ftJ6rrUw43ydsMGJ2Vaiy3xCa01OktKchtvIiSSQA0IUsRO
EXpdFVfgqosz2UJOuKywWXy5BXGi5zyNk52Pdxc+PDRifHiwchPGOpSTZh8BjuKqGFzZBtES1kL+
a69aLZxi9SbwbaVcMc/EdRvAbturWZy5nHbGZEaxkbExpMxkRetHQCckiIkSNuuvCZeq/SaovVb0
2220Rxwepyw7eHcl7hOdWWu+UNqMojrRMRpcaRGmOy2WkF2S/CbVqO5IupCfACJLWRFuqkiqt6LY
28c2mmqck86DqMwyfIOZdB1hmPEiQjgvY4IUdsgZbakOi86QIpEXMzFFUiJfl6IlrR2kVi2261r3
YEa2YJm75mXClQ3RZ7UyFAxzvEFRezjBAWLLy+6zScl+P4VaO1imnycn/VmHNnP10FBQCgFAKAUA
oBQCgKLVWSWrVGSWrWTJLaoySlVJFSCqVJBVKuiC9K0RBVKuiCtWIC0JCVAK1JAqQKAUAoBQCgFA
KAUAoBQCgFAKAUAoBQCgFAKA/9k=

------=_NextPart_000_0000_01C8B51B.516272D0
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.medicalnewstoday.com/images/blanktab.gif

R0lGODlhAgACAIAAAP///wAAACwAAAAAAgACAAACAoRRADs=

------=_NextPart_000_0000_01C8B51B.516272D0
Content-Type: text/css;
	charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
Content-Location: http://www.medicalnewstoday.com/css/pagelayout.css

BODY {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 78%; BACKGROUND: =
url(/images/backgroundgradient.jpg) #d1d8e0 repeat-x left top; =
PADDING-BOTTOM: 0px; MARGIN: 0px; COLOR: #333333; PADDING-TOP: 0px; =
FONT-FAMILY: Arial, Helvetica; TEXT-ALIGN: center; TEXT-DECORATION: none
}
#wrapper {
	BORDER-RIGHT: #999999 1px solid; PADDING-RIGHT: 0px; BORDER-TOP: 0px; =
MIN-WIDTH: 1000px; PADDING-LEFT: 0px; FONT-SIZE: 100%; Z-INDEX: 1; =
MIN-HEIGHT: 2100px; PADDING-BOTTOM: 0px; MARGIN: 0px auto; BORDER-LEFT: =
#999999 1px solid; WIDTH: 1000px; PADDING-TOP: 0px; BORDER-BOTTOM: =
#999999 1px solid; POSITION: relative; HEIGHT: auto; BACKGROUND-COLOR: =
#ffffff; TEXT-ALIGN: left
}
* HTML #wrapper {
	HEIGHT: 2100px
}
#maincontent {
	MARGIN-TOP: 50px; FONT-SIZE: 105%; MARGIN-LEFT: 185px; WIDTH: 815px; =
POSITION: relative; HEIGHT: auto
}
#maincontent_norightbar {
	MARGIN-TOP: 50px; FONT-SIZE: 105%; MARGIN-LEFT: 185px; WIDTH: 815px; =
POSITION: relative; HEIGHT: auto
}
#forumcontent {
	MARGIN-TOP: 50px; FONT-SIZE: 105%; MARGIN-LEFT: 185px; WIDTH: 815px; =
POSITION: relative; HEIGHT: auto
}
#maincontent {
	WIDTH: 490px; MARGIN-RIGHT: 320px
}
#forumcontent {
	WIDTH: 490px; MARGIN-RIGHT: 320px
}
#forumcontent {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; =
PADDING-TOP: 0px
}
#rightcol200 {
	PADDING-RIGHT: 7px; PADDING-LEFT: 20px; FLOAT: right; WIDTH: 245px
}
#rightcol380 {
	PADDING-RIGHT: 20px; PADDING-LEFT: 20px; FLOAT: right; WIDTH: 380px
}
#leftpad100 {
	PADDING-LEFT: 100px
}
#leftmenu {
	PADDING-LEFT: 0px; Z-INDEX: 3; LEFT: 10px; WIDTH: 159px; POSITION: =
absolute; TOP: 145px; HEIGHT: auto; TEXT-ALIGN: left
}
#menu {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; Z-INDEX: 2; BACKGROUND: #b3b1c0; =
PADDING-BOTTOM: 0px; WIDTH: 159px; PADDING-TOP: 0px; POSITION: relative
}
#menu A {
	BORDER-RIGHT: #999999 1px solid; PADDING-RIGHT: 4px; BORDER-TOP: =
#ffffff 1px solid; DISPLAY: block; PADDING-LEFT: 10px; FONT-SIZE: 11px; =
Z-INDEX: 1; BACKGROUND: #e2edf1; PADDING-BOTTOM: 5px; BORDER-LEFT: =
#999999 1px solid; WIDTH: auto; CURSOR: hand; COLOR: #0f4c78; =
PADDING-TOP: 5px; BORDER-BOTTOM: #999999 1px solid; HEIGHT: auto
}
#menu A:hover {
	BACKGROUND: #eeeeee; COLOR: #c60
}
#menu A:active {
	BACKGROUND: #ccc; COLOR: #060
}
#menu UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; WIDTH: 100%; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
.menuarrows {
	PADDING-RIGHT: 2px; FLOAT: right; POSITION: relative
}
* HTML #menu UL LI {
	FLOAT: left; HEIGHT: 1%
}
* HTML #menu UL LI A {
	HEIGHT: 1%
}
DIV#menu LI {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; =
PADDING-TOP: 0px; POSITION: relative
}
DIV#menu LI:hover {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; =
PADDING-TOP: 0px; POSITION: relative
}
DIV#menu LI UL {
	DISPLAY: none; LEFT: 100%; WIDTH: auto; POSITION: absolute; TOP: -100px
}
DIV#menu LI UL.sub2 {
	TOP: -122px
}
DIV#menu LI UL.sub3 {
	TOP: -142px
}
DIV#menu LI UL.sub4 {
	TOP: -162px
}
DIV#menu LI UL.sub5 {
	TOP: -182px
}
DIV#menu LI UL.sub6 {
	TOP: -202px
}
DIV#menu LI UL.sub7 {
	TOP: -222px
}
DIV#menu UL UL {
	BORDER-RIGHT: #dddddd 5px solid; BORDER-TOP: #dddddd 5px solid; =
BORDER-LEFT: 0px; BORDER-BOTTOM: #dddddd 5px solid
}
DIV#menu UL UL {
	DISPLAY: none
}
DIV#menu UL UL UL {
	DISPLAY: none
}
DIV#menu UL LI:hover UL UL {
	DISPLAY: none
}
DIV#menu UL LI:hover UL UL UL {
	DISPLAY: none
}
DIV#menu UL LI:hover UL {
	DISPLAY: block
}
DIV#menu UL UL LI:hover UL {
	DISPLAY: block
}
DIV#menu UL UL UL LI:hover UL {
	DISPLAY: block
}
#menu A.x {
	BORDER-LEFT: #999999 1px solid; BORDER-BOTTOM: #999999 1px solid
}
#menu A.x:visited {
	BORDER-LEFT: #999999 1px solid; BORDER-BOTTOM: #999999 1px solid
}
#menu A.x:hover {
=09
}
#menu A.x:active {
	BACKGROUND: #ccc; COLOR: #060
}
#menu A.z {
	PADDING-RIGHT: 0px; PADDING-LEFT: 10px; BACKGROUND: #ffffff; =
PADDING-BOTTOM: 1px; WIDTH: 200px; LINE-HEIGHT: 15px; PADDING-TOP: 1px; =
HEIGHT: 15px
}
#menu A.z:visited {
	PADDING-RIGHT: 0px; PADDING-LEFT: 10px; BACKGROUND: #ffffff; =
PADDING-BOTTOM: 1px; WIDTH: 200px; LINE-HEIGHT: 15px; PADDING-TOP: 1px; =
HEIGHT: 15px
}
#menu A.z:hover {
	PADDING-RIGHT: 0px; PADDING-LEFT: 10px; BACKGROUND: #ffffff; =
PADDING-BOTTOM: 1px; WIDTH: 200px; LINE-HEIGHT: 15px; PADDING-TOP: 1px; =
HEIGHT: 15px
}
#menu A.z:hover {
	BACKGROUND: #eeeeee
}
#menucatlist {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; LEFT: 1px; FLOAT: left; =
PADDING-BOTTOM: 0px; MARGIN: 0px; OVERFLOW: auto; WIDTH: 158px; =
PADDING-TOP: 0px; LIST-STYLE-TYPE: none; POSITION: relative; TOP: 1px; =
HEIGHT: 180px; BACKGROUND-COLOR: #ffffff
}
#menucatlist LI {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 92%; FLOAT: left; =
PADDING-BOTTOM: 0px; MARGIN: 0px; WIDTH: 98%; PADDING-TOP: 0px; =
BORDER-BOTTOM: #ddf 1px solid; POSITION: relative
}
#menucatlist A {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 5px; PADDING-BOTTOM: =
2px; WIDTH: auto; PADDING-TOP: 2px; HEIGHT: auto; WORD-WRAP: break-word
}
#menucatlist A:hover {
	BACKGROUND: #ccffcc; COLOR: #000
}
#rightmenu {
	Z-INDEX: 3; RIGHT: 0px; WIDTH: 300px; MARGIN-RIGHT: 10px; POSITION: =
absolute; TOP: 265px; HEIGHT: auto; BACKGROUND-COLOR: #ffffff; =
TEXT-ALIGN: left
}
#title {
	WIDTH: auto; HEIGHT: 215px; TEXT-ALIGN: left
}
#headerback {
	BACKGROUND: url(/images/bg.jpg) #ffffff repeat-x left top; WIDTH: auto; =
HEIGHT: 162px; TEXT-ALIGN: left
}
#titleback {
	BACKGROUND: url(/images/topbg.jpg) #002ab0 no-repeat left top; LEFT: =
50px; WIDTH: 922px; POSITION: relative; HEIGHT: 69px
}
#searchback {
	Z-INDEX: 1; LEFT: 446px; BACKGROUND-IMAGE: url(/images/adsbg.jpg); =
BACKGROUND-REPEAT: no-repeat; POSITION: absolute; TOP: 69px
}
.top-menu A {
	FONT-WEIGHT: normal; FONT-SIZE: 15px; LINE-HEIGHT: normal; FONT-FAMILY: =
"Trebuchet MS", Arial; TEXT-DECORATION: none
}
.top-menu A:hover {
	TEXT-DECORATION: underline
}
#titlebannernew {
	LEFT: 190px; POSITION: absolute; TOP: 155px
}

------=_NextPart_000_0000_01C8B51B.516272D0
Content-Type: text/css;
	charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
Content-Location: http://www.medicalnewstoday.com/css/default.css

TD {
	FONT-SIZE: 80%
}
TD.rightbar {
	FONT-SIZE: 11px; BACKGROUND-COLOR: #eeeeff
}
TD.sideline {
	BACKGROUND-IMAGE: url(/images/blacktab.gif); BACKGROUND-COLOR: #000000
}
H1 {
	FONT-SIZE: 17px
}
H2 {
	FONT-SIZE: 15px
}
H3 {
	FONT-SIZE: 13px
}
H2.sectiontitle {
	MARGIN-TOP: 4px
}
.smallwhite {
	FONT-SIZE: 75%; COLOR: #ffffff; TEXT-DECORATION: none
}
.smalltext {
	FONT-SIZE: 10px; TEXT-DECORATION: none
}
HR {
	BORDER-RIGHT: 0px solid; PADDING-RIGHT: 0px; BORDER-TOP: 1px solid; =
PADDING-LEFT: 0px; PADDING-BOTTOM: 4px; BORDER-LEFT: 0px solid; COLOR: =
#dddddd; PADDING-TOP: 3px; BORDER-BOTTOM: 0px solid; HEIGHT: 1px
}
.title {
	FONT-WEIGHT: bold; FONT-SIZE: 150%; COLOR: #000066; PADDING-TOP: 5px
}
A {
	TEXT-DECORATION: none
}
A:link {
	COLOR: #0000cc
}
A:visited {
	COLOR: #990099
}
A:hover {
	TEXT-DECORATION: underline
}
A:active {
	COLOR: #009900
}
.menutext {
	FONT-SIZE: 11px; COLOR: #000000
}
A.smalltext {
	FONT-SIZE: 90%
}
A.smalltext:hover {
	FONT-SIZE: 90%
}
SELECT {
	BORDER-RIGHT: #999999 1px solid; BORDER-TOP: #999999 1px solid; =
FONT-SIZE: 90%; BORDER-LEFT: #999999 1px solid; COLOR: #000000; =
LINE-HEIGHT: 14px; BORDER-BOTTOM: #999999 1px solid; BACKGROUND-COLOR: =
#ffffff
}
INPUT {
	BORDER-RIGHT: #999999 1px solid; PADDING-RIGHT: 1px; BORDER-TOP: =
#999999 1px solid; PADDING-LEFT: 2px; FONT-SIZE: 95%; PADDING-BOTTOM: =
1px; BORDER-LEFT: #999999 1px solid; PADDING-TOP: 1px; BORDER-BOTTOM: =
#999999 1px solid; FONT-FAMILY: Arial,Helvetica; BACKGROUND-COLOR: =
#ffffff
}
INPUT.list {
	FONT-WEIGHT: bold; FONT-SIZE: 95%
}
INPUT.radio {
	BORDER-RIGHT: 0px; BORDER-TOP: 0px; FONT-SIZE: 95%; BORDER-LEFT: 0px; =
BORDER-BOTTOM: 0px; BACKGROUND-COLOR: transparent
}
INPUT.submit {
	BORDER-RIGHT: #999999 1px solid; BORDER-TOP: #999999 1px solid; =
FONT-SIZE: 10px; BORDER-LEFT: #999999 1px solid; COLOR: #000000; =
BORDER-BOTTOM: #999999 1px solid; BACKGROUND-COLOR: #ffffff
}
.box {
	BORDER-RIGHT: #dddddd 1px solid; PADDING-RIGHT: 5px; BORDER-TOP: =
#dddddd 1px solid; PADDING-LEFT: 5px; PADDING-BOTTOM: 5px; MARGIN: 10px =
0px 0px; BORDER-LEFT: #dddddd 1px solid; PADDING-TOP: 5px; =
BORDER-BOTTOM: #dddddd 1px solid; BACKGROUND-COLOR: #f4f4ff; TEXT-ALIGN: =
left
}
.box2 {
	BORDER-RIGHT: #dddddd 1px solid; PADDING-RIGHT: 10px; BORDER-TOP: =
#dddddd 1px solid; PADDING-LEFT: 12px; PADDING-BOTTOM: 8px; MARGIN: 3px =
0px; BORDER-LEFT: #dddddd 1px solid; PADDING-TOP: 8px; BORDER-BOTTOM: =
#dddddd 1px solid; BACKGROUND-COLOR: #ffffff; TEXT-ALIGN: left
}
.box3 {
	BORDER-RIGHT: #cccccc 1px solid; PADDING-RIGHT: 10px; BORDER-TOP: =
#cccccc 1px solid; PADDING-LEFT: 12px; PADDING-BOTTOM: 5px; MARGIN: 0px =
2px 3px; BORDER-LEFT: #cccccc 1px solid; PADDING-TOP: 1px; =
BORDER-BOTTOM: #cccccc 1px solid; BACKGROUND-COLOR: #d2d2ff
}
.box4 {
	BORDER-RIGHT: #dddddd 1px solid; PADDING-RIGHT: 10px; BORDER-TOP: =
#dddddd 1px solid; PADDING-LEFT: 12px; PADDING-BOTTOM: 20px; MARGIN: 0px =
2px 20px; BORDER-LEFT: #dddddd 1px solid; WIDTH: 220px; PADDING-TOP: =
1px; BORDER-BOTTOM: #dddddd 1px solid; BACKGROUND-COLOR: #ffffff
}
.fronttitles2 {
	PADDING-RIGHT: 10px; BORDER-TOP: #cee0e8 1px solid; PADDING-LEFT: 12px; =
FONT-WEIGHT: bold; FONT-SIZE: 14px; BACKGROUND: =
url(/images/background_tab2.jpg) #ffffff repeat-x left top; =
MARGIN-BOTTOM: 10px; PADDING-BOTTOM: 20px; COLOR: #333333; PADDING-TOP: =
16px
}
.fronttitlesdate {
	FONT-WEIGHT: normal; FONT-SIZE: 12px; PADDING-TOP: 2px
}
.fronttitlesprevnext {
	FONT-WEIGHT: normal; FONT-SIZE: 12px; RIGHT: 7px; POSITION: relative; =
TOP: 0px
}
.fronttitles {
	BORDER-RIGHT: #aaaaaa 1px solid; PADDING-RIGHT: 10px; BORDER-TOP: =
#aaaaaa 1px solid; PADDING-LEFT: 10px; FONT-WEIGHT: bold; FONT-SIZE: =
14px; MARGIN-BOTTOM: 5px; PADDING-BOTTOM: 15px; BORDER-LEFT: #aaaaaa 1px =
solid; COLOR: #333333; PADDING-TOP: 16px; BORDER-BOTTOM: #aaaaaa 1px =
solid; BACKGROUND-COLOR: #e2edf1
}
OPTION.option1 {
	BACKGROUND-COLOR: #f4f4ff
}
OPTION.option2 {
	BACKGROUND-COLOR: #ffffff
}
TEXTAREA {
	BORDER-RIGHT: #999999 1px solid; BORDER-TOP: #999999 1px solid; =
FONT-SIZE: 12px; BORDER-LEFT: #999999 1px solid; BORDER-BOTTOM: #999999 =
1px solid; BACKGROUND-COLOR: #ffffff
}
A.menubutton1 {
	BORDER-RIGHT: #999999 1px solid; PADDING-RIGHT: 4px; BORDER-TOP: =
#ffffff 1px solid; DISPLAY: block; PADDING-LEFT: 10px; FONT-SIZE: 11px; =
PADDING-BOTTOM: 5px; BORDER-LEFT: #999999 1px solid; WIDTH: auto; =
CURSOR: hand; COLOR: #0f4c78; PADDING-TOP: 5px; BORDER-BOTTOM: #999999 =
1px solid; HEIGHT: auto
}
A.menubutton2 {
	BORDER-RIGHT: #999999 1px solid; PADDING-RIGHT: 4px; BORDER-TOP: =
#ffffff 1px solid; DISPLAY: block; PADDING-LEFT: 10px; FONT-SIZE: 11px; =
PADDING-BOTTOM: 5px; BORDER-LEFT: #999999 1px solid; WIDTH: auto; =
CURSOR: hand; COLOR: #0f4c78; PADDING-TOP: 5px; BORDER-BOTTOM: #999999 =
1px solid; HEIGHT: auto
}
A.menubutton1:hover {
	BACKGROUND: #e2edf1
}
A.menubutton2:hover {
	BACKGROUND: #e2edf1
}
A.menubutton1 {
	BACKGROUND-COLOR: #ffffff
}
A.menubutton2 {
	BACKGROUND-COLOR: #faf9d3
}
.menutitle {
	FONT-SIZE: 11px; BACKGROUND-REPEAT: no-repeat; FONT-FAMILY: Arial, =
Helvetica, sans-serif
}
.menutitle2b {
	FONT-SIZE: 11px; BACKGROUND-REPEAT: no-repeat; FONT-FAMILY: Arial, =
Helvetica, sans-serif
}
.menutitle {
	PADDING-RIGHT: 5px; PADDING-LEFT: 12px; BACKGROUND: =
url(/images/menutitle.jpg) #002ab0 repeat-x; PADDING-BOTTOM: 5px; COLOR: =
#ffffff; PADDING-TOP: 5px; TEXT-ALIGN: left
}
.articlecatlist {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; WIDTH: 150px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
.articlecatlist LI {
	PADDING-BOTTOM: 1px; MARGIN: 0px; WIDTH: 148px; PADDING-TOP: 1px
}
.headertab1 {
	BORDER-RIGHT: #666666 1px solid; PADDING-RIGHT: 9px; BORDER-TOP: =
#666666 1px solid; PADDING-LEFT: 8px; FONT-SIZE: 90%; BACKGROUND: =
url(/images/background_tab.jpg) #ffffff repeat-x left top; =
PADDING-BOTTOM: 9px; MARGIN: 0px 0px 10px; BORDER-LEFT: #666666 1px =
solid; PADDING-TOP: 12px; BORDER-BOTTOM: #ffffff 1px solid; TEXT-ALIGN: =
center
}
.headertab2 {
	BORDER-RIGHT: #aaaaaa 1px solid; PADDING-RIGHT: 5px; BORDER-TOP: =
#aaaaaa 1px solid; PADDING-LEFT: 5px; FONT-SIZE: 90%; PADDING-BOTTOM: =
7px; MARGIN: 0px 0px 10px; BORDER-LEFT: #aaaaaa 1px solid; PADDING-TOP: =
7px; BORDER-BOTTOM: #aaaaaa 1px solid; BACKGROUND-COLOR: #eeeeee; =
TEXT-ALIGN: center
}

------=_NextPart_000_0000_01C8B51B.516272D0
Content-Type: application/octet-stream
Content-Transfer-Encoding: quoted-printable
Content-Location: http://www.medicalnewstoday.com/scripts/AntiSpambotMailto.js

/****************************************************
 AntiSpambotMailto() - Documentation and encoder at:
    http://www.kenric.com/AntiSpambotMailto.html
****************************************************/
function AntiSpambotMailto(codelist, description, atagattr) {
	var thiscode, thischar;
	var CodeString =3D new String(codelist);
	var CodedArray =3D CodeString.split('|');
	var L =3D CodedArray.length;
	var AddrDecoded =3D "";
	for (var x=3D0; x < L; x++) {
		thiscode =3D CodedArray[x];
		thischar =3D String.fromCharCode( thiscode - L );
		AddrDecoded +=3D thischar;
	}
	atagattr =3D atagattr ? ' ' + atagattr : '';
	if (!description) description =3D AddrDecoded; // if no description =
supplied, display email address
	var strOutput =3D '<a href=3D"mailto:'+AddrDecoded+'"' + atagattr+' =
class=3D"spambotlink">' + description + '</a>';
	document.write(strOutput);
}
/************************************************************************=
***
Copyright (c) 2002 by Kenric L. Ashe - www.kenric.com - All rights =
reserved.

Redistribution and use in source and binary forms, with or without=20
modification, are permitted provided that the following conditions are =
met:

Redistributions of source code must retain the above copyright notice,=20
this list of conditions and the following disclaimer.=20

Redistributions in binary form must reproduce the above copyright =
notice,=20
this list of conditions and the following disclaimer in the =
documentation=20
and/or other materials provided with the distribution.=20

Neither the name of the Kenric.com nor the names of its contributors may =

be used to endorse or promote products derived from this software =
without=20
specific prior written permission.=20

THIS SOFTWARE IS PROVIDED BY THE COPYRIGHT HOLDERS AND CONTRIBUTORS=20
"AS IS" AND ANY EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT=20
LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR=20
A PARTICULAR PURPOSE ARE DISCLAIMED. IN NO EVENT SHALL THE COPYRIGHT=20
OWNER OR CONTRIBUTORS BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL,=20
SPECIAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT NOT LIMITED =

TO, PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES; LOSS OF USE, DATA, OR=20
PROFITS; OR BUSINESS INTERRUPTION) HOWEVER CAUSED AND ON ANY THEORY OF=20
LIABILITY, WHETHER IN CONTRACT, STRICT LIABILITY, OR TORT (INCLUDING=20
NEGLIGENCE OR OTHERWISE) ARISING IN ANY WAY OUT OF THE USE OF THIS=20
SOFTWARE, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGE.
*************************************************************************=
**/

------=_NextPart_000_0000_01C8B51B.516272D0--

